REGENERON PHARMACEUTICALS INC. - COMMON STOCK

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

08 Feb 2025 17:40:16 By Nasdaq GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

08 Feb 2025 15:55:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 Feb 2025 09:45:06 By NetDania Notify

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

04 Feb 2025 06:30:01 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 Feb 2025 09:46:44 By NetDania Notify

America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

23 Jan 2025 12:00:14 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Jan 2025 09:45:01 By NetDania Notify

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

13 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

13 Jan 2025 06:15:45 By Nasdaq GlobeNewswire

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

13 Jan 2025 06:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

10 Jan 2025 12:29:29 By NetDania Notify

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

07 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 Dec 2024 09:45:02 By NetDania Notify

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

19 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 Dec 2024 15:08:04 By NetDania Notify

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

17 Dec 2024 09:45:01 By NetDania Notify

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

17 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

16 Dec 2024 16:30:25 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 Dec 2024 09:45:56 By NetDania Notify